

---

*primary studies - published, non RCT*

## **Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.**

**Code:** PM33586024

**Year:** 2021 **Date:** 2021

**Author:** Colombo C

### **Study design (if review, criteria of inclusion for studies)**

Retrospective case-control study

### **Participants**

13 patients with a confirmed diagnosis of CF, homozygous for the Phe508del CFTR mutation

### **Interventions**

Lumacaftor/ivacaftor treatment (LUMA/IVA).

### **Outcome measures**

At the beginning and conclusion of the follow-up, all subjects received a modified 3 h OGTT, sampling at baseline, and at 30 min intervals for plasma glucose, serum insulin, and c-peptide concentrations to evaluate glucose tolerance, and quantify by modeling beta-cell insulin secretion responsiveness to glucose, insulin clearance and insulin sensitivity.

### **Main results**

LUMA/IVA did not produce differences in glucose tolerance, insulin secretory parameters, clearance and sensitivity with respect to matched controls over one-year follow-up.

### **Authors' conclusions**

We found no evidence of improvements in glucose tolerance mechanisms in patients with CF after one-year treatment with LUMA/IVA.

<http://dx.doi.org/10.1007/s40618-021-01525-4>

### **See also**

J Endocrinol Invest. 2021 Feb 13. doi: 10.1007/s40618-021-01525-4.

### **Keywords**

Child; Adult; Adolescent; Aminophenols; CFTR Modulators; Genetic Predisposition to Disease; Orkambi; pharmacological\_intervention; VX-770; ivacaftor; lumacaftor; VX-809;